Aphria Completes First Commercial Shipment of Medical Marijuana
Ample Inventory on Hand to Satisfy Strong Patient Demand
LEAMINGTON, ONTARIO--(Dec 11, 2014) - Aphria Inc. (TSX VENTURE:APH) is pleased to announce that it has completed its first commercial shipment of medical marijuana, just two weeks following the company's receipt of its final license from Health Canada.
"I am delighted to announce that initial demand for our product is strong and, with our first commercial sales and shipment of medical marijuana completed yesterday, we are officially open for business," said Vic Neufeld, Chief Executive Officer of Aphria. "Patients have been registering on our Aphria website since the moment we announced receipt of our license, and with close to 100 kilograms of product ready, or soon to be ready, we are geared up to satisfy the robust demand."
Aphria's three state-of-the-art light and computer controlled glass greenhouses are located within a 450,000 square foot greenhouse facility in Leamington, Ontario. Currently, Aphria has 22,000 square feet of production space with plans to significantly increase capacity in the next 12 to 24 months.
Added Neufeld, "Management has a long and proven track record of owning and operating large commercial scale greenhouse businesses. This invaluable experience together with the cost-saving attributes of our well-established greenhouse operations form the fundamental cornerstones of Aphria and provide us with key competitive advantages in the nascent Canadian medical marijuana industry."
Aphria, a company continued under the laws of the Province of Ontario and based in Leamington, Ontario, is in the business of producing, supplying and selling medical marijuana pursuant to the Marihuana for Medical Purposes Regulations (the "MMPR"). Under the MMPR, Health Canada is responsible for the oversight of commercial medical marijuana growers such as Aphria. Aphria's common shares are listed on the TSX Venture Exchange under the ticker symbol "APH".
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "intend" and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to Aphria's intended business focus and anticipated future demand for medical marijuana. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of Aphria to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.